SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : INHL - Inhale Therapeutics - Pulmonary Insulin! -- Ignore unavailable to you. Want to Upgrade?

To: Dan Ross who wrote (77)1/29/1998 9:18:00 AM
From: PeterR1700  Respond to of 225
 
Dan - I've been following (sidelines) INHL for quite awhile now. Terrific idea...competitors? Would greatly appreciate knowing the opinion of your colleague.

Peter



To: Dan Ross who wrote (77)2/4/1998 10:30:00 PM
From: Marvin Frank  Read Replies (1) | Respond to of 225
 
Dear Dan, As a physician I feel the potential for growth is excellent as pointed out in recent Business Week article but stock only rose
1 1/2 pts and then dropped. It appears that INHL is overpriced. The idea of inhalation to absorb systemic drugs or insulin is medically feasible and pioneering. There is a competitor you might like to check out: Aradigm (ARDM) at a price of $10approx.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News